Free Trial

Arrowhead Pharmaceuticals (ARWR) SEC Filings & 10K Form

Arrowhead Pharmaceuticals logo
$18.71 +0.11 (+0.59%)
(As of 11/20/2024 ET)

Recent Arrowhead Pharmaceuticals SEC Filings

DateFilerForm TypeView
11/15/2024
7:34 PM
Arrowhead Pharmaceuticals (Issuer)
Lu Hongbo (Reporting)
Form 5
Annual statement of changes in beneficial ownership of securities  
11/14/2024
8:38 AM
Arrowhead Pharmaceuticals (Subject)
Avoro Capital Advisors LLC (Filed by)
Form SC 13G
10/16/2024
8:15 AM
Arrowhead Pharmaceuticals (Subject)
STATE STREET CORP (Filed by)
Form SC 13G/A
07/03/2024
4:27 PM
Arrowhead Pharmaceuticals (Issuer)
Oliver Tracie (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2024
3:09 PM
Arrowhead Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/06/2024
5:04 PM
Arrowhead Pharmaceuticals (Issuer)
Vakiener Victoria (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/02/2024
1:39 PM
Arrowhead Pharmaceuticals (Subject)
Vakiener Victoria (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/10/2024
1:03 PM
Arrowhead Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G/A
04/03/2024
5:05 PM
Arrowhead Pharmaceuticals (Issuer)
Hamilton James C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2024
3:30 PM
Arrowhead Pharmaceuticals (Subject)
Hamilton James C (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/20/2024
6:06 PM
Arrowhead Pharmaceuticals (Issuer)
Lu Hongbo (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/19/2024
3:38 PM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/18/2024
6:00 PM
Arrowhead Pharmaceuticals (Issuer)
Lu Hongbo (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
03/08/2024
4:54 PM
Arrowhead Pharmaceuticals (Issuer)
Myszkowski Kenneth Allen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2024
4:30 PM
Arrowhead Pharmaceuticals (Subject)
Myszkowski Kenneth Allen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/02/2024
4:25 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/31/2024
3:57 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/26/2024
4:28 PM
Arrowhead Pharmaceuticals (Filer)
Form DEFA14A
01/24/2024
11:57 AM
Arrowhead Pharmaceuticals (Subject)
STATE STREET CORP (Filed by)
Form SC 13G/A
01/23/2024
3:14 PM
Arrowhead Pharmaceuticals (Subject)
BlackRock Inc. (Filed by)
Form SC 13G/A
01/17/2024
5:32 PM
Arrowhead Pharmaceuticals (Issuer)
Hamilton James C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
4:22 PM
Arrowhead Pharmaceuticals (Subject)
Hamilton James C (Reporting)
Form 144/A
01/16/2024
5:06 PM
Arrowhead Pharmaceuticals (Issuer)
Vakiener Victoria (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2024
5:06 PM
Arrowhead Pharmaceuticals (Issuer)
Ferrari Mauro (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2024
5:06 PM
Arrowhead Pharmaceuticals (Issuer)
Waddill William D. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2024
5:06 PM
Arrowhead Pharmaceuticals (Issuer)
GIVEN DOUGLAS B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/11/2024
3:48 PM
Arrowhead Pharmaceuticals (Subject)
Vakiener Victoria (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/11/2024
3:38 PM
Arrowhead Pharmaceuticals (Subject)
Arrowhead Pharmaceuticals (Subject)
Waddill William D. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/11/2024
3:22 PM
Arrowhead Pharmaceuticals (Subject)
Ferrari Mauro (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/08/2024
4:16 PM
Arrowhead Pharmaceuticals (Issuer)
San Martin Javier (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2024
4:16 PM
Arrowhead Pharmaceuticals (Issuer)
Myszkowski Kenneth Allen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2024
4:17 PM
Arrowhead Pharmaceuticals (Issuer)
Oliver Tracie (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2024
6:58 PM
Arrowhead Pharmaceuticals (Issuer)
O'Brien Patrick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2024
7:02 PM
Arrowhead Pharmaceuticals (Issuer)
Hamilton James C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2024
4:33 PM
Arrowhead Pharmaceuticals (Subject)
Hamilton James C (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/05/2024
4:14 PM
Arrowhead Pharmaceuticals (Subject)
Hamilton James C (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/05/2024
3:39 PM
Arrowhead Pharmaceuticals (Subject)
Myszkowski Kenneth Allen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/05/2024
3:21 PM
Arrowhead Pharmaceuticals (Subject)
San Martin Javier (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/05/2024
3:08 PM
Arrowhead Pharmaceuticals (Subject)
Oliver Tracie (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/04/2024
4:25 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/04/2024
4:27 PM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

01/04/2024
12:49 PM
Arrowhead Pharmaceuticals (Subject)
O'Brien Patrick (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/04/2024
12:06 PM
Arrowhead Pharmaceuticals (Subject)
O'Brien Patrick (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/04/2024
12:25 PM
Arrowhead Pharmaceuticals (Subject)
O'Brien Patrick (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/04/2024
11:24 AM
Arrowhead Pharmaceuticals (Subject)
Hamilton James C (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/02/2024
3:44 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/22/2023
4:04 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/21/2023
3:34 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/19/2023
2:51 PM
Arrowhead Pharmaceuticals (Issuer)
GIVEN DOUGLAS B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2023
2:52 PM
Arrowhead Pharmaceuticals (Issuer)
Vakiener Victoria (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2023
2:54 PM
Arrowhead Pharmaceuticals (Issuer)
OLUKOTUN ADEOYE Y (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2023
2:55 PM
Arrowhead Pharmaceuticals (Issuer)
PERRY MICHAEL S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2023
2:41 PM
Arrowhead Pharmaceuticals (Issuer)
Waddill William D. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/05/2023
4:16 PM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/29/2023
3:10 PM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/22/2023
1:31 PM
Arrowhead Pharmaceuticals (Issuer)
San Martin Javier (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ARWR) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners